NVNO

Business Context and Reporting Period

Company: enVVeno Medical Corp (NVNO)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: A late-stage medical device company developing the enVVe System, a first-in-class transcatheter replacement venous valve for severe Chronic Venous Insufficiency (CVI). In April 2026, the FDA granted Investigational Device Exemption (IDE) approval for the pivotal TAVVE study, expected to commence in the second half of 2026.

Key Financial Metrics

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by 46% in Q2 2026 compared to Q2 2025, and by 33% on a year-to-date basis. This improvement is primarily driven by a significant reduction in operating expenses.
• Expense Reductions:
  • R&D Expenses: Decreased by 28% in Q2 and 23% YTD. This was due to lower follow-up costs for the prior VenoValve pivotal study, partially offset by increased development costs for the new enVVe System.
  • SG&A Expenses: Decreased by 59% in Q2 and 44% YTD. Reductions were driven by lower stock-based compensation ($1.0M decrease in Q2) and the absence of non-recurring charges recorded in 2025, including a $0.6M reserve for uncollectible prepaid clinical costs and $0.3M in severance.
• Investment Portfolio: Short-term investments decreased from $25.1 million to $18.6 million as the company utilized cash for operations. Unrealized losses on fixed-income securities were minimal ($22k in Q2 2026).
• Capital Structure: The company executed a 1-for-35 reverse stock split effective January 20, 2026. All share data in the filing has been retroactively adjusted.

Guidance, Outlook, and Risks

• Clinical Outlook: The TAVVE pivotal study is expected to begin in the second half of 2026. Stage 1 involves 10 patients for 30-day safety review; Stage 2 will enroll 220 patients (165 treatment, 55 control). FDA post-marketing approval eligibility is projected one year after the 220th patient enrollment.
• Liquidity and Burn Rate: Management anticipates the cash burn rate will increase from $3–$4 million per quarter to $4–$5 million per quarter in the second half of 2026 due to the upcoming pivotal study. With $21.5 million in cash and investments as of June 30, 2026, the company expects to fund operations into the third quarter of 2027.
• Capital Needs: The company will need to raise additional capital in the future. Failure to secure financing would have a material adverse effect on operations.
• Risks: As a smaller reporting company, the filing defers to the 2026 10-K for detailed risk factors. Key inherent risks include the success of clinical trials, regulatory approval timelines, and the ability to commercialize the product.

Investor Verification Checklist

• Cash Runway: Verify the projected burn rate of $4–$5 million per quarter against the current $21.5 million cash balance to confirm the Q3 2027 liquidity runway.
• Study Commencement: Monitor the start date of the TAVVE pivotal study (expected H2 2026) and the 30-day safety results from the initial 10-patient cohort.
• Capital Raising: Assess the status of the At-the-Market (ATM) offering and potential need for additional equity financing before Q3 2027.
• Expense Trends: Confirm that the reduction in SG&A is sustainable and not solely due to the one-time non-recurring charges in 2025.
• Reverse Split Impact: Ensure all historical share data and per-share metrics are correctly adjusted for the 1:35 reverse stock split.